2014 Fiscal Year Final Research Report
IL13Ra2, therapeutic target of melanoma, identified by unique antibody screening technology.
| Project/Area Number |
25830123
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Tokyo University of Pharmacy and Life Science |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Keywords | IL13Ra2 / イムノトキシン / 悪性黒色腫 / モノクローナル抗体 |
|---|
| Outline of Final Research Achievements |
Current approach of cancer therapy, such as chemotherapy, radiotherapy and surgery, has been treated for many years, but it is still hard to cure completely. Especially in chemotherapy, one of long-lasting problem is the side effect of administrated drug, following the interference of regimen.
To overcome this issue, we developed unique targeting technology coupled with monoclonal antibody (MoAb) screening system that enable us to utilize both selectivity and specificity. To establish selective and specific antibody that target cancer biomarker, classical hybridoma library was upgraded with our unique probe that is recombinant toxin protein fused with Fc-binding protein (DT3C), to generate immunotoxin library. Here we present; (A) principle of our targeting technology, and (B) discovery of anti-IL13Ra2 MoAb (clone NS66) that has potent activity as DT3C-based immunotoxin, (C) characterization of IL13Ra2 as novel melanoma biomarker as well as therapeutic target.
|
| Free Research Field |
腫瘍医科学
|
